May 18, 2017

Phase 3 Trial Shows Promising Results for Imfinzi in Subset of NSCLC Patients

News

Patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) who have not progressed following standard platinum-based chemotherapy and radiation therapy, may greatly benefit from treatment with the PD-L1 inhibitor ... Read more

October 27, 2016

Immunotherapy Showing Promise in Treating Advanced Lung Cancer in Phase 1/2 Trial

News

Durvalumab, an experimental immunotherapy drug, may be a potential treatment approach for patients with advanced lung or head and neck cancers, according to preliminary data from a Phase 1/2 trial. Preliminary ... Read more